Meeting Information
Tuesday, October 22, 2019 at 9:30 AM in Room 1100 of the Longworth House Office Building.

Notice of Meeting

Markup of:

• H.R. 3398, the “Pathways to Health Careers Act of 2019”
• H.R. 3, the “Lower Drug Costs Act Now Act of 2019”
• H.R. 4650, the “Medicare Dental Act of 2019”
• H.R. 4665, the “Medicare Vision Act of 2019”
• H.R. 4618, the “Medicare Hearing Act of 2019”

Additional Markup Materials:

• Amendment in the Nature of a Substitute to H.R. 3398
• WAM Description of Amendment in the Nature of a Substitute to H.R. 3398 (Green Sheet) 
• JCT Description of H.R. 3
• Amendment in the Nature of a Substitute to H.R. 3
• JCT Description of Amendment in the Nature of a Substitute to H.R. 3 (Green Sheet) 
• Amendment in the Nature of a Substitute to H.R. 4650
• WAM Description of Amendment in the Nature of a Substitute to H.R. 4650 (Green Sheet) 
• Amendment in the Nature of a Substitute to H.R. 4665
• WAM Description of Amendment in the Nature of a Substitute to H.R. 4665 (Green Sheet) 
• Amendment in the Nature of a Substitute to H.R. 4618
• WAM Description of Amendment in the Nature of a Substitute to H.R. 4618 (Green Sheet) 

Republican Amendments Offered: 

1. Amendment filed by Rep. Smith to H.R. 3398, which would  strike the Amendment in the Nature of a Substitute to H.R. 3398 and replace it with the JOBS for Success Act
2. Amendment filed by Rep. Walorski to H.R. 3398, which would dedicate any funding above the historic level of $85 million per year to a “pay for outcomes” financing structure
3. Amendment filed by Rep. LaHood to H.R. 3398, which would give priority to grants that include direct involvement of employers in the development of training and grants that use earn and learn models
4. Amendment filed by Rep. Brady to H.R. 3, which would reduce out-of-pocket spending on drugs while preserving the hope of future careers
5. Amendment filed by Rep. Brady to H.R. 3, which would redesign and modernize the Medicare Part D program to add an out-of-pocket spending cap for beneficiaries and for other purposes
6. Amendment filed by Rep. Smith to H.R. 3, which would improve incentives of the add-on payment and cap the add-on amount for Part B drugs
7. Amendment filed by Rep. Wenstrup to H.R. 3, which would improve transparency of out-of-pocket costs for patients getting their Part B drugs and reduce out-of-pocket costs for patient who are getting their Part B drugs in certain hospital settings or by a hospital-owned physician practice
8. Amendment filed by Rep. Arrington to H.R. 3, which would require a partial passthrough of Part D rebates at the point of sale
9. Amendment filed by Rep. Reed to H.R. 3, which would expand the cap on PDP offerings from three to four and allow plans that passthrough a portion of rebates at the point of sale to offer six PDPs
10. Amendment filed by Rep. Reed to H.R. 3, which would require rebates on insulin products in Part D to be delivered at the point of sale
11. Amendment filed by Rep. Wenstrup to H.R. 3, which would require hospitals to pass along saving form the 340B program directly to consumers to help lower their out-of-pocket costs for drugs
12. Amendment filed by Rep. Ferguson to H.R. 3, which would promote competition in the market for drugs and biological products by, among other policies, stopping anti-competitive practices and reforming certain exclusivity conditions
13. Amendment filed by Rep. Walorski to H.R. 3, which would strike the 95 percent excise tax imposed on certain drug manufacturers during noncompliance periods, repeal the 2.3 percent excise tax on certain medical devices, and set the income threshold for the medical expense deduction at 7.5 percent of adjusted gross income permanently
14. Amendment filed by Rep. Nunes to H.R. 3, which would strike Title I of H.R. 3
15. Amendment filed by Rep. Holding to H.R. 3, which would eliminate international reference pricing from the bill
16. Amendment filed by Rep. LaHood to H.R. 3, which would exempt any drug used to treat or cure Alzheimer’s disease from price setting
17. Amendment filed by Rep. Walorski to H.R. 3, which would exempt any drug used to treat or cure Cancer from price setting
18. Amendment filed by Rep. Smith to H.R. 3, which would exempt any drug used to treat or cure any rare disease or any other disease most prevalent to seniors from price setting
19. Amendment filed by Rep. Kelly to H.R. 3, which would allow new drug applications for unmet medical needs that benefit Medicare beneficiaries
20. Amendment filed by Rep. LaHood to H.R. 3, which would require that no provision of H.R. 3 shall result in a shift in investment of pharmaceutical biotechnology or drug manufacturing jobs from the U.S. to other foreign countries, including China
21. Amendment filed by Rep. Smith to H.R. 3, which would require no provision of H.R. 3 be implemented until the Secretary of Health and Human Services certifies in writing that H.R. 3 will not reduce access to life-saving medications in rural areas within the United States
22. Amendment filed by Rep. Ferguson to H.R. 3, which would require that no provision of H.R. 3 be implemented until the Secretary of Health and Human Services certifies in writing that H.R. 3 will not reduce patient access to physicians, including oncologists, in rural areas within the United States
23. Amendment filed by Rep. Arrington to H.R. 3, which would create a Chief Pharmaceutical Negotiator at the Office of the United States Trade Representative
24. Amendment filed by Rep. Schweikert to H.R. 3, which would instruct the HHS Secretary to convene a panel of technical experts to examine alternative federal payment models for disruptive health care therapies and innovation
25. Amendment filed by Rep. Schweikert to H.R. 3, which would create a medication adherence pilot program
26. Amendment filed by Rep. Kelly to H.R. 3, which would provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act, and for other purposes
27. Amendment filed by Rep. Estes to H.R. 3, which would require the savings be reinvested into the HI Medicare Trust Fund to improve solvency
28. Amendment filed by Rep. Rice to H.R. 3, which would provide relief from Obamacare’s tax on branded drugs